StonvexLoading…
StonvexStonvexStonvexThe Schall Law Firm is recruiting investors for a class action securities fraud lawsuit against Atara Biotherapeutics (ATRA), alleging the company made false statements about manufacturing issues and deficiencies in its tabelecleucel ALLELE study. The lawsuit covers investors who purchased securities between May 20, 2024 and January 9, 2026, claiming the company overstated drug prospects while concealing regulatory risks.
The Schall Law Firm is seeking investors to join a class action lawsuit against Atara Biotherapeutics for alleged securities fraud. The company allegedly made false and misleading statements regarding manufacturing problems and deficiencies in its ALLELE study for tabelecleucel, overstating the drug's prospects and concealing regulatory risks. Investors who purchased securities between May 20, 2024 and January 9, 2026 are encouraged to participate.
Summary and sentiment are generated by AI for educational purposes. Always verify with the original source before making investment decisions.
Risk warning
Investing in equities carries significant risk, including the potential loss of your entire investment. Volatility, liquidity, geopolitical, and currency risks can all materially affect outcomes. Past performance does not guarantee future results. Nothing on Stonvex is investment advice, a recommendation, or a solicitation to buy or sell any security. Stonvex is not a registered investment advisor (RIA), broker-dealer, or financial planner. You should consult a licensed advisor before making investment decisions and only invest capital you can afford to lose.
© 2026 Stonvex. All rights reserved.
Service not available to residents of: Belarus, China, Cuba, France, Germany, India, Iran, Japan, North Korea, Russia, Sudan, Syria. See Terms. You must be 18 years or older to use this service.